Key result
Long-term low-dose aspirin did not prevent the development of clinical type 2 diabetes in initially healthy women compared to placebo (rate ratio 1.01; 95% CI 0.91-1.11).
Why the study?
Does chronic low-dose aspirin prevent the development of clinical type 2 diabetes in initially healthy women aged ≥45 years?
RCT (n=38,716)
double-blind
randomly assigned
Does chronic low-dose aspirin prevent the development of clinical type 2 diabetes in initially healthy women aged ≥45 years?
Relative Risk: 1.01 (95% CI 0.91–1.11)
Absolute Event Rate: 4.39% vs 4.37%
Long-term low-dose aspirin does not prevent the development of clinical type 2 diabetes in initially healthy women.
No takes yet. Share an insight, caveat, or question.
Low-dose aspirin should not be used for diabetes prevention in healthy women; confirms absence of benefit in this RCT.
Pradhan et al. (2008) conducted an RCT in type 2 diabetes (n=38,716). low-dose aspirin vs. placebo was evaluated on Documented clinical type 2 diabetes (rate ratio 1.01, 95% CI 0.91-1.11). Long-term low-dose aspirin did not prevent the development of clinical type 2 diabetes in initially healthy women compared to placebo (rate ratio 1.01; 95% CI 0.91-1.11).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: